Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug

Core Insights - Ionis Pharmaceuticals reported a fourth quarter adjusted loss of $1.15, which was better than the Wall Street estimate of $1.32 [1] - The company's sales reached $203 million, exceeding the consensus estimate of $156.09 million [1] - Commercial revenue for the fourth quarter increased by 64% year-over-year, while annual revenue grew by 49% compared to 2024 [1] Sales Performance - The increase in sales was primarily driven by Tryngolza (olezarsen) product sales, which generated $50 million in the fourth quarter, a 56% increase over the prior quarter, and $108 million for the full year [2] - Dawnzera (donidalorsen) generated $7 million in product sales during its first full quarter on the market [2] Management Commentary - The CEO of Ionis stated that 2025 was a defining year for the company, marked by successful independent launches and positive data readouts, positioning Ionis for continued success in 2026 [3] Future Guidance - Ionis Pharmaceuticals expects fiscal 2026 sales to be between $800 million and $825 million, which is below the consensus estimate of $909.84 million [4] - The company anticipates an adjusted operating loss of $500 million to $550 million, wider than the consensus of $400.5 million, primarily due to the top-line guidance miss [5] - The company reiterated its goal to achieve cash flow breakeven by 2028 [5] Stock Performance - Ionis shares experienced a decline of 4.06%, trading at $81.98 at the time of publication [5]